

Matthew Mossanen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/212326/publications.pdf>

Version: 2024-02-01

92
papers

1,264
citations

430874

18
h-index

414414

32
g-index

93
all docs

93
docs citations

93
times ranked

1821
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Association between Operative Time and Short-Term Radical Cystectomy Complications. <i>Urologia Internationalis</i> , 2023, 107, 273-279. | 1.3 | 2 |
| 2 | Robotic-assisted radical cystectomy is associated with lower perioperative mortality in octogenarians. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 163.e19-163.e23. | 1.6 | 4 |
| 3 | Association of Race With Cancer-Related Financial Toxicity. <i>JCO Oncology Practice</i> , 2022, 18, e271-e283. | 2.9 | 23 |
| 4 | Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. <i>European Urology</i> , 2022, 81, 466-473. | 1.9 | 12 |
| 5 | Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 528-528. | 1.6 | 7 |
| 6 | Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas. <i>Journal of Clinical Oncology</i> , 2022, 40, 1275-1280. | 1.6 | 6 |
| 7 | Preoperative anemia is associated with increased radical cystectomy complications. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 382.e7-382.e13. | 1.6 | 1 |
| 8 | The impact of smoking on radical cystectomy complications increases in elderly patients. <i>Cancer</i> , 2021, 127, 1387-1394. | 4.1 | 10 |
| 9 | Patient factors predict complications after partial nephrectomy: validation and calibration of the Preoperative Risk Evaluation for Partial Nephrectomy (PREP) score. <i>BJU International</i> , 2021, 127, 369-374. | 2.5 | 6 |
| 10 | Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era?. <i>Urology</i> , 2021, 147, 199-204. | 1.0 | 9 |
| 11 | Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. <i>European Urology Focus</i> , 2021, 7, 124-131. | 3.1 | 31 |
| 12 | Impact of angiotensin inhibitors on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 432-432. | 1.6 | 0 |
| 13 | Cost-effectiveness analysis of pembrolizumab for BCG-unresponsive carcinoma in situ of the bladder.. <i>Journal of Clinical Oncology</i> , 2021, 39, 395-395. | 1.6 | 0 |
| 14 | Genomic landscape of variant urinary tumor histologies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 467-467. | 1.6 | 4 |
| 15 | Temporal trends in the incidence of distant-stage bladder cancer among young individuals. <i>International Journal of Urology</i> , 2021, 28, 704-705. | 1.0 | 2 |
| 16 | Comparison of comorbidity indices for prediction of morbidity and mortality after major surgical procedures. <i>American Journal of Surgery</i> , 2021, 222, 998-1004. | 1.8 | 7 |
| 17 | Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. <i>BJU International</i> , 2021, 128, 607-614. | 2.5 | 10 |
| 18 | Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ of the Bladder. <i>Journal of Urology</i> , 2021, 205, 1326-1335. | 0.4 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | The Epidemiology of Bladder Cancer. Hematology/Oncology Clinics of North America, 2021, 35, 445-455. | 2.2 | 28 |
| 20 | Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 436.e1-436.e10. | 1.6 | 4 |
| 21 | Delay in surgery for cT1b-2 kidney cancer beyond 90 days is associated with poorer survival: implications for prioritization during the COVID-19 pandemic. Minerva Urology and Nephrology, 2021, 73, 404-406. | 2.5 | 3 |
| 22 | Clinical characterization of radiation-associated muscle-invasive bladder cancer. Urology, 2021, 154, 208-214. | 1.0 | 3 |
| 23 | Best practices for assessing and reporting tobacco use in urology oncology practice and research. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 446-451. | 1.6 | 1 |
| 24 | Cyclophosphamide-associated bladder cancers and considerations for survivorship care: A systematic review. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 678-685. | 1.6 | 3 |
| 25 | Defining Factors Associated with High-quality Surgery Following Radical Cystectomy: Analysis of the British Association of Urological Surgeons Cystectomy Audit. European Urology Open Science, 2021, 33, 1-10. | 0.4 | 7 |
| 26 | The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study. Prostate Cancer and Prostatic Diseases, 2020, 23, 144-150. | 3.9 | 9 |
| 27 | Trends in Adherence to Thromboprophylaxis Guideline in Patients Undergoing Radical Cystectomy. Urology, 2020, 135, 44-49. | 1.0 | 5 |
| 28 | The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65 years. Cancer, 2020, 126, 496-505. | 4.1 | 19 |
| 29 | Beyond bladder cancer surveillance: building a survivorship clinic. BJU International, 2020, 125, 2-3. | 2.5 | 3 |
| 30 | Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. World Journal of Urology, 2020, 38, 2227-2236. | 2.2 | 12 |
| 31 | Risk factors and reasons for reoperation after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 269-277. | 1.6 | 13 |
| 32 | The cost of obesity in radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 932.e9-932.e14. | 1.6 | 5 |
| 33 | AUTHOR REPLY. Urology, 2020, 140, 121. | 1.0 | 0 |
| 34 | Delayed blood transfusion is associated with mortality following radical cystectomy. Scandinavian Journal of Urology, 2020, 54, 290-296. | 1.0 | 1 |
| 35 | Physician and facility drivers of spending variation in locoregional prostate cancer. Cancer, 2020, 126, 1622-1631. | 4.1 | 1 |
| 36 | Alvimopan Is Associated With a Reduction in Length of Stay and Hospital Costs for Patients Undergoing Radical Cystectomy. Urology, 2020, 140, 115-121. | 1.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e651-e659. | 1.9 | 7 |
| 38 | Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 439-439. | 1.6 | 101 |
| 39 | Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2.. <i>Journal of Clinical Oncology</i> , 2020, 38, 507-507. | 1.6 | 12 |
| 40 | Resource utilization and cost efficacy analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e19390-e19390. | 1.6 | 0 |
| 41 | Dissecting outcomes of patients (pts) with <ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5043-5043. | 1.6 | 0 |
| 42 | Impact of histology and toxicities on outcomes of patients with muscle invasive bladder cancer receiving neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 540-540. | 1.6 | 0 |
| 43 | Resource utilization analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 474-474. | 1.6 | 0 |
| 44 | Hospital Charges for Urologic Surgery Episodes of Care Are Rising Despite Declining Costs. <i>Mayo Clinic Proceedings</i> , 2019, 94, 995-1002. | 3.0 | 2 |
| 45 | Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer. <i>Cancer</i> , 2019, 125, 3164-3171. | 4.1 | 35 |
| 46 | The bladder cancer conundrum: how do we treat the right tumour with the right treatment, at the right time?. <i>BJU International</i> , 2019, 123, 748-749. | 2.5 | 0 |
| 47 | Inferring bladder cancer research prioritization from patient-generated online content. <i>World Journal of Urology</i> , 2019, 37, 1145-1150. | 2.2 | 9 |
| 48 | Does overlapping surgery result in worse surgical outcomes? A systematic review and meta-analysis. <i>American Journal of Surgery</i> , 2019, 218, 181-191. | 1.8 | 6 |
| 49 | Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. <i>World Journal of Urology</i> , 2019, 37, 2059-2065. | 2.2 | 40 |
| 50 | Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?. <i>Cancer</i> , 2019, 125, 1449-1458. | 4.1 | 56 |
| 51 | Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 23-31.e3. | 1.9 | 40 |
| 52 | Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. <i>BJU International</i> , 2019, 124, 40-46. | 2.5 | 17 |
| 53 | Genomic profiling of variant urinary tract tumor histologies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 450-450. | 1.6 | 0 |
| 54 | Cost and cost-effectiveness studies in urologic oncology using large administrative databases. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 213-219. | 1.6 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2018, 45, 143-154. | 1.8 | 17 |
| 56 | Well-being beyond the bladder. How do we improve the overall health of patients with bladder cancer?. <i>BJU International</i> , 2018, 121, 489-491. | 2.5 | 2 |
| 57 | Editorial Comment. <i>Journal of Urology</i> , 2018, 199, 712-712. | 0.4 | 0 |
| 58 | Addressing Financial Toxicity: The Role of the Urologist. <i>Journal of Urology</i> , 2018, 200, 43-45. | 0.4 | 14 |
| 59 | Exploring Patterns of Mitomycin C Use in Community Practice Urology. <i>Urology Practice</i> , 2018, 5, 7-14. | 0.5 | 2 |
| 60 | Associations of specific postoperative complications with costs after radical cystectomy. <i>BJU International</i> , 2018, 121, 428-436. | 2.5 | 30 |
| 61 | Quality Improvement Efforts in Radical Cystectomy: From Prehab to Rehab. <i>European Urology</i> , 2018, 73, 372-373. | 1.9 | 5 |
| 62 | The impact of readmission hospital on failure-to-rescue rates following major urologic cancer surgery. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 156.e1-156.e7. | 1.6 | 2 |
| 63 | Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. <i>European Urology</i> , 2018, 73, 374-382. | 1.9 | 62 |
| 64 | Treating Patients With Bladder Cancer: Is There an Ethical Obligation to Include Smoking Cessation Counseling?. <i>Journal of Clinical Oncology</i> , 2018, 36, 3189-3191. | 1.6 | 11 |
| 65 | The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 500.e11-500.e19. | 1.6 | 10 |
| 66 | Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy. <i>European Urology Oncology</i> , 2018, 1, 143-148. | 5.4 | 19 |
| 67 | Charge-to-Cost Ratio Varies among Common Urological Surgery Procedures. <i>Urology Practice</i> , 2018, 5, 349-350. | 0.5 | 2 |
| 68 | A contemporary population-based analysis of the incidence, cost, and outcomes of postoperative delirium following major urologic cancer surgeries. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 341.e15-341.e22. | 1.6 | 25 |
| 69 | Shared decision making for prostate cancer screening: Reality or farce?. <i>Journal of Clinical Oncology</i> , 2018, 36, 107-107. | 1.6 | 3 |
| 70 | Impact of late Medicaid expansion on prostate cancer screening.. <i>Journal of Clinical Oncology</i> , 2018, 36, 141-141. | 1.6 | 2 |
| 71 | Perioperative outcomes of aspirin use in radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 150-150. | 1.6 | 0 |
| 72 | Perioperative outcomes of aspirin use in partial nephrectomy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 698-698. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Trends and morbidity for minimally invasive versus open cytoreductive nephrectomy in the management of metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 632-632. | 1.6 | 1 |
| 74 | Impact of sexual orientation on contemporary rates of prostate cancer screening.. Journal of Clinical Oncology, 2018, 36, 122-122. | 1.6 | 0 |
| 75 | Utilization and outcomes of chemoprophylaxis for the prevention of venous thromboembolism following radical cystectomy: A population-based study.. Journal of Clinical Oncology, 2018, 36, 491-491. | 1.6 | 0 |
| 76 | Incidence and predictors of mortality following major urologic cancer surgery.. Journal of Clinical Oncology, 2018, 36, 435-435. | 1.6 | 0 |
| 77 | Hospital variation in outcomes after surgery for prostate cancer.. Journal of Clinical Oncology, 2018, 36, 28-28. | 1.6 | 0 |
| 78 | Individual, interpersonal, and organisational factors of healthcare conflict: A scoping review. Journal of Interprofessional Care, 2017, 31, 282-290. | 1.7 | 78 |
| 79 | Prophylactic Antibiotics and Postoperative Complications of Radical Cystectomy: A Population Based Analysis in the United States. Journal of Urology, 2017, 198, 297-304. | 0.4 | 35 |
| 80 | Exploring exposure to Agent Orange and increased mortality due to bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 627-632. | 1.6 | 6 |
| 81 | Approach to the Patient with High-Risk Prostate Cancer. Urologic Clinics of North America, 2017, 44, 635-645. | 1.8 | 6 |
| 82 | Urinary Catheter Management for Nonurologists: A Resident Driven Educational Initiative. Urology Practice, 2017, 4, 85-90. | 0.5 | 0 |
| 83 | Patient driven care in the management of prostate cancer: analysis of the United States military healthcare system. BMC Urology, 2017, 17, 56. | 1.4 | 9 |
| 84 | Cost-effectiveness analysis of magnetic resonance imaging-ultrasound fusion biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer.. Journal of Clinical Oncology, 2017, 35, 25-25. | 1.6 | 1 |
| 85 | Characterizing the costs of complications after cystectomy: Can we target the primary drivers?. Journal of Clinical Oncology, 2017, 35, 304-304. | 1.6 | 0 |
| 86 | Patient-centered risk stratification of disposition outcomes following radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 235.e17-235.e23. | 1.6 | 22 |
| 87 | Overuse of Antimicrobial Prophylaxis in Community Practice Urology. Journal of Urology, 2015, 193, 543-547. | 0.4 | 44 |
| 88 | Identification of underserved areas for urologic cancer care. Cancer, 2014, 120, 1565-1571. | 4.1 | 27 |
| 89 | The burden of bladder cancer care. Current Opinion in Urology, 2014, 24, 487-491. | 1.8 | 138 |
| 90 | Surgical pathology and the patient: a systematic review evaluating the primary audience of pathology reports. Human Pathology, 2014, 45, 2192-2201. | 2.0 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 91 | Use and Outcomes of Extended Antibiotic Prophylaxis in Urological Cancer Surgery. Journal of Urology, 2014, 192, 425-429. | 0.4 | 49 |
| 92 | Readability of urologic pathology reports: The need for patient-centered approaches. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1091-1094. | 1.6 | 18 |